Glympse Bio Company

Glympse Bio develops a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases. The company’s technology uses precisely engineered diagnostic agents that interrogate the body for certain disease states, and then carry the message to the urine for analysis. Glympse Bio’s platform technology was originally developed at MIT, and is founded by a team of world-renowned experts in nanomedicine and biomedical engineering.
Industry: Early Drug Development, Clinical Development
Headquarters: Cambridge, Massachusetts, United States
Founded Date: 2015-01-01
Employees Number: 11-50
Funding Status: Early Stage Venture
Investors Number: 17
Total Funding: 96024986
Estimated Revenue: $1M to $10M
Last Funding Date: 2021-12-17
Last Funding Type: Venture - Series Unknown

Visit Website
Register and Claim Ownership